Breaking Finance News

BTIG Research upgraded Kite Pharma Inc (NASDAQ:KITE) to Buy in a report released today.

Yesterday Kite Pharma Inc (NASDAQ:KITE) traded 0.00% even at $82.10. The company’s 50-day moving average is $175.64 and its 200-day moving average is $113.31. The last stock close price is down 58.68% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 100 shares of the stock traded hands, down from an average trading volume of 2,005,000

BTIG Research has upgraded Kite Pharma Inc (NASDAQ:KITE) to Buy in a report released on 6/08/2017.

Performance Chart

Kite Pharma Inc (NASDAQ:KITE)

With a total market value of $0, Kite Pharma Inc has with a one year low of $39.82 and a one year high of $179.95 .

A total of 11 brokers have issued a research note on Kite Pharma Inc. Six brokerages rating the company a strong buy, 7 firms rating the stock a buy, 0 equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally 0 firms rating the stock a sell with a consensus target price of $74.18.

About Kite Pharma Inc (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.